Hanx Biopharmaceuticals (Wuhan) , Ltd. EBIT

Hanx Biopharmaceuticals (Wuhan) , Ltd. (3378.HK) currently reports a EBIT of $970M as of June 2019. That compares with $830M in the prior-year period — up 16.1% year over year. That is below the Healthcare sector average of $2T. Use the charts on this page to explore Hanx Biopharmaceuticals (Wuhan) , Ltd.'s EBIT history and peer comparisons.

Hanx Biopharmaceuticals (Wuhan) , Ltd.'s EBIT increased from $830M to $970M — a 16.1% year-over-year increase (period ending June 2019). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Hanx Biopharmaceuticals (Wuhan) , Ltd.'s EBIT of $970M is lower than the Healthcare sector average of $2T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Hanx Biopharmaceuticals (Wuhan) , Ltd. reported $970M in EBIT as of June 2019. That compares with $830M in the prior-year period — up 16.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $970M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $2T. From there, open related valuation or income-statement pages for Hanx Biopharmaceuticals (Wuhan) , Ltd., and consider following 3378.HK for alerts when major investors trade the stock.